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ABSTRACT 
Growth of Staphylococcus aureus with the NSAID salicylate increases phenotypic 
resistance (SAPAR), and the frequency at which heritable resistance occurs to various 
antibiotics (SAGAR). This study describes the effect of salicylate on heritable and 
phenotypic resistance to a set of antibiotics for laboratory and multi-drug resistant strains 
of S. aureus and investigates the link between resistance and SAGAR. Drug gradient plates 
were used to determine phenotypic resistance to antibiotics targeting DNA replication, 
transcription, translation and the cell wall in the presence or absence of salicylate. To 
measure heritable resistance, mutation frequencies were determined for each antibiotic in 
the presence and absence of salicylate. Salicylate significantly increased mutation 
frequency of SH1000 to ciprofloxacin 27- fold from 4.9 x 10-8 to 8.5 x 10-7. A significant 
8.5- fold increase was observed for LAC from 5.2 x 10-7 to 2.1 x 10-6. Conversely, 
salicylate significantly decreased mutation frequency for SH1000 to lincomycin 0.035-fold 
from 3.4 x 10-7 to 1.3 x 10-7. Deletion of the general stress sigma factor sigB encoding σB 
in SH1000 resulted in decreased heritable and phenotypic resistance, signifying the 
importance of σB in the full expression of both phenotypes. Metabolite profiling revealed 
downregulation of glycolysis, TCA, pentose phosphate pathway, and amino acid 
metabolism. The downregulation of the TCA cycle was confirmed as observed through an 
increase in NAD+ at growth toxic concentrations of salicylate. Salicylate has been shown to 
result in ROS accumulation and disruption of proton motive force in mitochondria. 
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SAGAR was only detected for fluoroquinolones, which have been shown to impair TCA 
cycle and result in ROS accumulation. Examination of ROS under growth-toxic 
concentrations of salicylate did not reveal a significant increase in ROS levels. Also, the 
combination of ciprofloxacin and salicylate did not result in an increase in ROS levels. 
Despite this, addition of the antioxidant glutathione abrogated SAGAR for ciprofloxacin in 
SH1000 but not for SAPAR. Analysis of SAGAR with NSAIDs benzoate and acetyl 
salicylic acid revealed a necessity for the ortho hydroxyl group on salicylate to fully 
express SAGAR. These results suggest that salicylate has pleiotropic effects on S. aureus 
that include antimicrobial resistance, altered metabolic flux and accumulation of ROS as 
well as unidentified regulatory genes.  
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CHAPTER ONE: INTRODUCTION 
1.1 NSAIDs and salicylate 
Non-steroidal anti-inflammatory drugs (NSAIDs) have analgesic and anti-
inflammatory properties and are used in the treatment and control of inflammatory 
conditions and in the treatment of various cancers [1-5]. NSAIDs inhibit 
cyclooxygenases, a class of enzymes responsible for producing mediators of 
inflammation including prostaglandins, prostanoids, thromboxanes. NSAIDs are among 
the most widely prescribed drugs, with approximately 100 million prescriptions filled 
annually in the USA alone [6]. Acetylsalicylic acid (aspirin) was the first synthesized 
NSAID, and is known for its extensive analgesic, anti-pyretic and anti-inflammatory 
activity [2, 3]. Salicylate, the primary metabolite of aspirin, is also recognized for its 
strong analgesic and antipyretic properties [3, 7] and in addition, is broadly used in oral 
and topical medications, as a preservative in foods, and in various commercial 
applications [8].  
 
1.2 The effects of salicylate on eukaryotes 
 Salicylate and its chemical derivatives have been used since 400 B.C for their 
analgesic and antipyretic properties, and more recently as antiplatelet agents for the 
prevention of myocardial infarction and stroke [9, 10]. Salicylate and acetyl salicylic acid 
(aspirin) have also been shown to prevent colon cancer [11], and to have chemoprotective 
properties against lung and breast cancer [12]. This is believed to result from 
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enhancement by salicylate of the mitochondrial permeability transition-dependent 
apoptosis (MPT), which acts by promoting apoptosis of transformed cells [12].  
 Salicylate has been shown to decrease the threshold for the onset of mitochondrial 
permeability transition (MPT) [13, 14]. The MPT involves the formation of a non-
specific pore across the inner membrane permitting the free distribution of ions, solutes, 
and small-molecular-weight molecules across the membrane [15]. The collapse of the 
mitochondrial membrane potential and uncoupling of the electron transport chain from 
ATP production has been shown to promote MPT. This disruption or collapse is also 
associated with the loss of matrix calcium and glutathione, increased oxidation of thiols, 
and further depolarization of the inner mitochondrial membrane, which increases the 
gating potential for the MPT pore [15-19]. Salicylate can induce MPT at low 
concentrations, resulting in an increase in the vulnerability of rat hepatocytes to necrosis 
from oxidant stress [11], while high concentrations of salicylate (>3 mM) can lead to 
MPT and cell death. It is believed that salicylate-dependent onset of the MPT may be 
responsible for Reye’s syndrome [11]. Reye’s syndrome is a rare and severe illness in 
children with a mean mortality rate of 40% [20]. The etiological cause is presently 
unknown. However, this disease is believed to correlate with the use of salicylates and/or 
other anti-pyretic drugs [21-24].  
 
1.3 The effects of salicylate on bacteria 
 Salicylate has been shown to induce a number of distinct morphological and 
physiological changes in bacteria. Importantly, when grown in the presence of sub-
inhibitory concentrations of salicylate, clinically significant species of bacteria including 
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Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa and others, express 
increased levels of intrinsic antibiotic resistance [7, 25-27]. Importantly, these effects are 
induced under concentrations of salicylate that do not impair bacterial growth rates, 
suggesting that they are specific to salicylate. Increased resistance to antibiotics in the 
presence of salicylate has been attributed to the alteration in membrane-associated 
proteins such as porins and transporters, leading to a reduction in drug accumulation [7]. 
This salicylate-associated phenotypic resistance is non-heritable, and results in reduced 
susceptibility to mechanistically and structurally distinct antimicrobials [26-37]. 
Phenotypic resistance has been attributed to a weak acid effect, which is thought to be 
due to an increase in membrane potential and altered permeability and a decrease in 
internal pH, the pH gradient, and the proton motive force [38]. Foulds et al. [39] 
demonstrated a 3- to 5-fold decrease in permeation of cephalosporins through the outer 
membrane of E. coli induced with salicylate.  
 Salicylate has been shown to alter energy metabolism in many organisms. For 
example, in E. coli, growth with salicylate altered the expression of over 130 genes [41]. 
In addition, it was shown to dissipate the proton gradient across the inner membrane, 
chelate iron, induce heat shock as well as inhibit growth [40-41]. Similarly, in Bacillus 
subtilis, salicylate was shown to impair energy metabolism as observed through a down-
regulation of ATPases, suggesting energy impairment [41]. Salicylate also induced the 
general stress sigma factor B (sigB), and sigB dependent genes in B. subtilis. In addition, 
salicylate decreases metabolism of purines, pyrimidines, coenzymes, as well as 
metabolism of carbohydrates involved in glycolysis [42]. Growth with salicylate has 
similar modulatory effects on metabolism in S. aureus. Therefore, it is of no surprise that 
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salicylate altered metabolism in S. aureus, resulting in inhibition of glycolysis as seen in 
the downregulation of glyceraldehyde-3-phosphate dehydrogenase (gapA2) and 
phosphoglucoisomerase (pgi) [43]. The findings by Riordan et al. [43] indicate an 
impairment of growth and overall alteration in central and energy metabolism. This 
existing data suggest that salicylate has pleiotropic effects on bacterial cells that are 
physiochemical and metabolic.  
 
1.4 Staphylococcus aureus 
Staphylococcus aureus is a low GC Gram-positive, non-spore forming bacteria 
that was discovered in the 1880s [44]. S. aureus is a facultative anaerobe [46] that can 
grow at temperatures between 25°C to 43°C and at pH levels of 4.8 to 9.4 [45]. S. aureus 
mainly colonizes the membranes and skin of warm-blooded animals, and infections range 
from benign skin lesions to life-threatening systemic illnesses such as endocarditis and 
osteomyelitis [45]. The Center for Disease Control and Prevention estimated in 2005 that 
there were 31.8 culture confirmed invasive methicillin resistant S. aureus (MRSA) 
infections in the U.S. per 100,000 individuals, which amounted to 94,360 cases [47]. The 
primary mode of transmission is through direct contact, usually skin-to-skin contact with 
a colonized or infected individual, although contact with contaminated objects or surfaces 
also plays a role [48-51]. S. aureus is capable of producing many toxins and is able to 
acquire resistance to many antibiotics [45]. Currently, greater than 60% of S. aureus 
isolates are resistant to methicillin and some strains have developed resistance to more 
than twenty antimicrobial agents [52]. Acquisition of resistance in S. aureus commonly 
results from either gene mutations leading to drug target modifications or reduction of 
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drug efficacy, as well as acquisition of a resistance gene(s) from other organisms by 
some form of horizontal genetic exchange [53]. The genome of S. aureus is 
approximately 2.8 Mbp with a GC content of 33% [45, 52, 53].  
 
1.5 Antibiotic Resistance in S. aureus 
Staphylococcus aureus is exceptionally resistant to a wide-range of antibiotics 
(for review see [44]). This resistance evolved in S. aureus via horizontal gene transfer, 
chromosomal mutation and antibiotic selection [44]. Antibiotic resistance in S. aureus 
emerged in a series of waves [44]. The first wave of resistance began in the mid 1940s 
where penicillin-resistant strains began to surface in hospitals shortly after its 
introduction [54, 55]. Introduction of methicillin in 1960 initiated the second wave of 
resistance. Methicillin is a narrow spectrum β-lactam antibiotic that inhibits cross-
linkages between the linear peptidoglycan polymer chains that make up a major 
component of the Gram positive cell wall [56]. It was as early as 1961 that resistance to 
methicillin was detected in S. aureus. The mecA gene, encoding alternative penicillin 
binding protein 2 (PBP2) responsible for the methicillin resistance phenotype, was not 
identified until more than twenty years later. The emergence of methicillin resistant S. 
aureus (MRSA) strains led to an increase in the use of vancomycin [57, 58]. Vancomycin 
is a glycopeptide antibiotic used in the prophylaxis and treatment of serious infections 
caused by Gram positive bacteria [57, 58]. Vancomycin acts by inhibiting proper cell 
wall synthesis through formation of hydrogen bond interactions with the terminal D-ala-
D-ala moieties of the NAG/NAM peptides [57, 58]. The first vancomycin intermediate 
resistant S. aureus (VISA) strain was reported in 1997 with MICs <16 µg/ml [59]. The 
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first VRSA strain was isolated in June 2002 with high-level vancomycin-resistance and 
an MIC=1024 µg/ml [59]. This isolate was also found to be resistant to aminoglycosides, 
rifampin, and tetracycline. This VRSA strain was later determined to acquire the 
vancomycin resistance gene through horizontal gene transfer from Enterococcus faecalis 
[57, 58]. The invasion of MRSA into the community constitutes the fourth and latest 
wave of resistance. It is during this wave that community associated (CA) MRSA and 
vancomycin resistant strains began to emerge [44]. Despite all the resistance only two 
antibiotics besides vancomycin, linezolid and daptomycin have been approved for 
therapy since the 1990s [60].  
 
1.6 Salicylate associated phenotypic and genotypic antibiotic resistance in S. aureus 
Phenotypic antibiotic resistance was first characterized in E. coli. Resistance to 
chloramphenicol and ampicillin was induced during incubation with the weak acids 
acetate or benzoate, the NSAIDs aspirin and salicylate, and other chemical repellants 
such as dimethyl sulfoxide (DMSO), and 1-methyl-2-pyrrolidinone, [29]. Importantly, 
cells were sensitive to the antibiotics when grown in the absence of these inducers, and 
thus resistance was described to be inducible and non-heritable. Salicylate-inducible 
antibiotic resistance in E. coli was subsequently found to be due, in part, to increased 
transcription of the marRAB operon [25]. The marRAB operon consists of marR, which 
encodes a negative regulator of the operon, and marA, a transcriptional activator. 
Salicylate has been found to interact with the ligand binding domain of MarR, interfering 
with its ability to efficiently recognize the mar operator, marO. This, in turn, leads to 
induction of MarA and a decrease in antibiotic accumulation by reduced production of 
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outer membrane porins OmpF and OmpC, and a concomitant increase in the production 
of the multidrug efflux pump AcrAB [61, 62]. Salicylate has also been shown to induce 
phenotypic antibiotic resistance in Salmonella typhimurium. When grown in the presence 
of salicylate, S. typhimurium developed increased resistance to chloramphenicol, and 
enoxacin. This was found to be due to the induction of a S. typhimurium mar system 
homologous to the mar operon of E. coli [28]. Klebsiella pneumoniae also exhibits 
increased phenotypic resistance to tetracycline, β-lactams, clindamycin and norfloxacin 
in the presence of salicylate, which has been reported to be due to increased transcription 
of ramA, encoding a MarA homolog [35].  
Phenotypic antimicrobial resistance is also induced by salicylate in S. aureus. 
When exposed to salicylate, S. aureus develops increased resistance to fluoroquinolones, 
the steroid antibiotic fusidic acid, hard surface disinfectants and ethidium bromide [26, 
33]. The mechanism for phenotypic resistance in S. aureus is thought to be achieved in 
part by the upregulation of drug efflux pumps including NorA, NorB, MdeA and SepA 
[7, 63-66] and through alterations in membrane permeability [33, 43, 67-71]. As in other 
bacteria, phenotypic resistance in S. aureus appears to be dependent on Mar family 
homologs, such as the Sar-family of proteins, MgrA, as well as the general stress 
resistance protein sigma factor B [66, 72-76]. Sigma factor B is one of two alternative 
sigma factors in S. aureus [77] and is essential for the general chemical and physical 
stress response of the organism [78]. sigB regulation has been found to be intertwined 
with the expression of SarA, which regulates the expression of a number of 
staphylococcal virulence factors [78-81]. Analyses by Riordan et al. [71] determined that 
altered expression of sigB and sarA is not required for the salicylate-inducible 
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mechanism. Riordan et al. [43] also observed impairment in the glycolytic pathway as 
seen through a decrease in glyceraldehyde-3-phosphate dehydrogenase (gapA2) and 
phosphoroglucoisomerase (pgi) in response to salicylate stress, which is supported by 
evidence in eukaryotes [8, 9, 82-84].  
Salicylate has been shown to alter the level of resistance as well as the frequency 
at which antibiotic resistance occurs in S. aureus [7, 26, 33, 85]. Specifically, salicylate 
has been observed to increase the frequency at which S. aureus mutates to become 
resistant to fluoroquinolones and fusidic acid [7, 26, 33, 85]. The addition of salicylate 
significantly increased the number of ciprofloxacin and norfloxacin resistant S. aureus 
colonies compared to resistant colonies selected in the absence of salicylate; 
ciprofloxacin-resistant mutants arose at mutation frequencies of 1.8 x 10-9 on plates 
containing ciprofloxacin, compared to a mutation frequency of 1.8 x 10-7 on plates 
containing ciprofloxacin and salicylate [33]. Colonies selected from ciprofloxacin in the 
presence of salicylate containing plates had MICs > 0.8 mg/l, which was higher than 
colonies selected in the absence of salicylate [33]. The mutations leading to 
fluoroquinolone and fusidic acid resistance in these isolated were heritable, and 
resistance to these antibiotics occurred at unrelated loci within the S. aureus genome [86, 
87]. The underlying mechanism of salicylate-associated genotypic resistance [26, 33] and 
the extent to which salicylate alters resistance to other antibiotics is currently unknown. 
 
1.7 Hypothesis and aims of the study 
This study seeks to understand the basis of salicylate-associated genotypic 
antibiotic resistance (SAGAR) in the deadly human pathogen, S. aureus. The overarching 
hypothesis is that the SAGAR phenotype is common to mechanistically and structurally 
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distinct antibiotics, and is attributable to the effect(s) of salicylate on S. aureus 
metabolism. The following aims test this hypothesis: 
 
Aim 1. Assess the ability of salicylate to alter the frequency at which genotypic 
resistance to mechanistically and structurally distinct antibiotics occurs in S. aureus. 
 
Aim 2. Examine the role for salicylate-associated metabolic stress in the genotypic 
antibiotic resistance phenotype. 
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CHAPTER TWO: CHARACTERIZATION OF THE SALICYLATE-
ASSOCIATED GENOTYPIC ANTIBIOTIC RESISTANCE PHENOTYPE IN S. 
AUREUS 
 
2.1 Background  
The nonsteroidal anti-inflammatory drug (NSAID) salicylate has been shown to 
increase the frequency at which heritable (genotypic) fusidic acid and ciprofloxacin 
resistance occurs in S. aureus [7, 26, 33, 43, 69, 70]. These antibiotics have distinct 
cellular targets, and are structurally unique. This salicylate-associated antibiotic 
resistance (SAGAR) suggests that salicylate, and perhaps other NSAIDs, may have a 
generalized effect on mutation frequency in the cell. Yet, salicylate has not been shown 
to be directly mutagenic by the Ames test [85], which suggests that this increase in 
mutation frequency may result from the alteration of an existing physiological process 
which occurs in combination with specific antibiotic chemistries or antibiotic mechanistic 
activities. For example, bactericidal drugs such as ciprofloxacin have been shown to 
increase oxidation of NADH via the electron transport chain [88, 89], resulting in 
formation of the reactive oxygen species (ROS) superoxide [90-92]. Superoxide and 
other ROS damage iron-sulfur clusters, making ferrous iron available for oxidation by the 
Fenton reaction [88, 89]. The Fenton reaction leads to hydroxyl radical formation, which 
damages DNA, proteins and lipids, ultimately resulting in cell death [88, 89]. 
Subinhibitory concentrations of certain antibiotics, specifically compounds whose 
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primary mode of action is DNA damage, are known to enhance mutation rates in bacteria 
[93, 94]. This elevation in mutation frequency is partly a result of transcriptional changes 
in genes responsible for DNA repair and preservation of the integrity of the genome [93, 
94]. This effect is also observed with rifampin, an antibiotic that interacts specifically 
with the β subunit of the bacterial RNA polymerase encoded by the rpoB gene [95]. 
Growth with salicylate also leads to a non-heritable (phenotypic) increase in 
resistance to many antimicrobials [7, 26, 33, 43, 69-71, 96]. As in E. coli, this salicylate-
inducible phenotypic resistance in S. aureus partly results from a decrease in drug 
accumulation due to alterations in membrane permeability, proton motive force, and 
efflux [7, 25, 26, 33, 36, 37, 43, 69-71, 96]. A number of proteins have been determined 
to be involved in this phenotypic resistance mechanism of S. aureus including: multidrug 
efflux pumps NorA, NorB, MdeA, and SepA as well as other chromosomally encoded 
efflux pumps [7, 63-66, 97]; the global regulatory protein MgrA [66, 73, 76]; 
staphylococcal accessory regulator (SarA) [74]; and alternative sigma factor B (SigB) 
[70]. Mutations in the S. aureus genes encoding these proteins resulted in increased [70, 
74, 98-100] or decreased [63-65, 80, 97, 99] susceptibility to antimicrobials. Phenotypic 
resistance may allow the cell prolonged exposure to low levels of antibiotic, leading to 
the acquisition of mutations and high level heritable (genotypic) resistance [101]. 
Currently, the salicylate-associated genotypic antibiotic resistance (SAGAR) 
phenotype has only been described for a limited number of antibiotics, or for antibiotics, 
which are not commonly indicated for S. aureus infections. In addition, the relationship 
between salicylate-inducible phenotypic resistance and the SAGAR phenotype is 
unknown. The following experiments are designed to examine the SAGAR phenotype, 
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and to test the hypothesis that growth of S. aureus with salicylate increases the frequency 
at which resistance to structurally and mechanistically distinct antibiotics occurs. 
 
 
2.2 Methods 
Bacterial strains and culture media and conditions 
S. aureus strains used in this study are listed in Table 2.1. Unless otherwise noted, 
strains were grown aerobically at 37°C with shaking (200 RPM) in baffled Erlenmeyer 
flasks (5:1 volume ratio of flask:media). Cultures were generally maintained in tryptic 
soy broth (TSB) or TSB with 1.5% agar (TSA), and stocked at -80°C in TSB with the 
addition of 20% (vol/vol) glycerol.  
 
Antibiotics and NSAIDs 
All antibiotics and nonsteroidal anti-inflammatory drugs (NSAIDs) were 
dissolved, filter sterilized and stored according to Material Safety Data Sheet guidelines 
(Version 3 [102]). The antibiotics used in this study included ciprofloxacin (2.5 mg/ml in 
0.1 N HCl), norfloxacin (5 mg/ml in 0.1 N HCl), fusidic acid (1 mg/ml in sterile water), 
vancomycin (1 mg/ml in sterile water), tetracycline (1 mg/ml in sterile water), rifampin 
500 µg/ml in methanol), oxacillin (1 mg/ml in sterile water) and lincomycin (1 mg/ml in 
sterile water). The NSAIDs and weak acids used in this study included: sodium salicylate 
(0.5 M in sterile water), acetylsalicylic acid (3 mM in sterile water) and sodium benzoate 
(0.5 M in sterile water). 
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Table 2.1. Bacterial Strains and Plasmids 
 
Strain name Relevant Characteristics Source/reference 
S. aureus   
SH1000 rsbU+ derivative of 8325-4 Dr. Lindsey Shaw, USF, [103] 
SaRNH-1 SH1000Δ sigB Dr. Lindsey Shaw, USF, [103] 
Newman Wild-type Dr. John Gustafson, NMSU, [104] 
SaRNH-2 Newman ΔmgrA Dr. John Gustafson, NMSU, [105] 
LAC USA300 CA-MRSA Dr. Lindsey Shaw, USF, [106] 
E. coli   
 MG1655 Wild-type Dr. James Riordan, USF, [107] 
 
 
 
Table 2.2 Primers used in this study 
 
Primer name Sequence (5’à3’) 
grlA+2402 ACTTGAAGATGTTTTAGGTGAT 
grlA+2961 TTAGGAAATCTTGATGGCAA 
grlB+1520 CGATTAAAGCACAACAAGCAAG 
grlB+1894 CATCAGTCATAATAATT CTC 
gyrA+2311 AATGAACAAGGTATGACACC 
gyrA+2533 TACGCGCTTCAGTATAACGC 
gyrB+1400 CAGCGTTAGATGTAGCAAGC 
gyrB+1650 CCGATTCCTGTACCAAATGC 
All primers were designed based on this study. 
 
Determination of mutation frequency  
The protocol for mutation frequency to antibiotic resistance was adapted from 
Foster, 2006 [108]. Three independent cultures were grown under standard conditions in 
TSB overnight before sampling 0.1 ml onto TSA alone, TSA with antibiotic at ½ X, 1X, 
and 2X MIC, TSA with NSAID, or TSA with antibiotic and NSAID. Plates were 
incubated for 24 h before counting colony forming units (CFU/ml). Mutation frequency 
(µ) and fold-change in mutation frequency was calculated from colony counts using the 
following equations: 
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 Eq. 2.1:  µμ  antibiotic = CFU  (Antibiotic)CFU  (TSA)  
 Eq. 2.2:  µμ  NSAID = CFU   Antibiotic+ NSAIDCFU  (NSAID)  
 
Fold change was calculated using the following equation: 
 Eq. 2.3:  Fold  Change =   µμAntibiotic+ NSAIDAntibiotic  
 
 
Differences in the mutation frequency between control and treatment cultures were 
compared using a t-test (α=0.05, n≥3) (R). 
 
Antibiotic susceptibility by the minimum inhibitory concentration assay (MIC)  
MICs were determined as described [109] with slight adaptations. Overnight S. 
aureus MHB cultures were diluted to an OD600 = 0.01 in fresh MHB. A stock of the 
desired antibiotic was prepared at two times the highest concentration in MHB. Serial 2-
fold dilutions of respective drugs were prepared in MHB. Of the diluted culture, 1 ml was 
added to each tube to achieve the final concentration with a final volume of 2 ml. A 
negative control containing the growth medium plus antibiotic was prepared. A positive 
control containing the growth medium and culture was also prepared. The set of tubes 
were incubated static overnight at 37°C. The MIC for each independent sample was 
recorded, as the lowest concentration of antibiotic at which there was no visible growth.  
 
S. aureus chromosomal DNA extraction  
A single colony of S. aureus SH1000 was grown under standard conditions 
overnight. The following day the cells were pelleted by centrifugation at 3,700 x g for 10 
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min. Pelleted cells were resuspended in 5 ml 1X TE buffer (pH 8.0) and centrifuged as 
above. Cell pellets were then resuspended in 600 µl of 1X TE buffer and transferred to a 
1ml Eppendorf tube containing 0.5 cm3 of 0.1 mm glass beads. The tube was placed in a 
bead beater (Mini-bead beater-16, Biospec) and pulsed at 10 sec intervals for a total of 60 
seconds without a break. Homogenates were then centrifuged for 5 min at 13,200 x g. 
The supernatant was transferred to a sterile microtube, and 0.2 ml of 1.6% (vol/vol) 
sarkosyl and a total of 25 µg of proteinase K was added to the tube and incubated at 60°C 
for 60 min. Eight-hundred microliters of phenol/chloroform/isoamyl was added, 
vortexed, and centrifuged at 13,200 x g for 5 min. The upper aqueous layer was 
transferred to a fresh Eppendorf tube, and 0.5 ml isopropyl alcohol and 100 µl of 3 M 
sodium acetate were added and mixed by inversion. This was allowed to incubate at -
80°C for 15-30 min. The samples were then centrifuged at 13,200 x g for 5 min, and the 
supernatant was carefully discarded. Five-hundred microliters of 70% ethanol was added 
to the pellet and centrifuged at 13,200 x g for 5 min.  The supernatant was then discarded. 
The samples were allowed to air dry for 3-4 min at room temperature with the lid open. 
Two-hundred microliters of ddH2O was used to resuspend the DNA.  
 
Sequencing of target site modifications in antibiotic resistant mutants  
Antibiotic resistant and susceptible isolates were passaged three times in the 
absence of antibiotic before MICs were determined. DNA from two representative 
isolates was extracted and PCR was used to amplify a 559-bp fragment of grlA using 
primers grlA+2402/grlA+2961, a 374-bp fragment of grlB using primers 
grlB+1520/grlB+1894, a 222-bp fragment of gyrA using primers gyrA+2311/gyrA+2533, 
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and a 250-bp fragment of gyrB using primers gytB+1400/gyrB+1650 (Table 2.2). grlAB 
and gyrAB were amplified at an annealing temperature of 55°C, and an extension time of 
50 seconds for 30 cycles. Products were confirmed by ethidium bromide agarose gel 
electrophoresis and were purified using Qiagen purification kit (Qiagen, Valencia, CA) 
per the manufacturer’s instructions. Products were sequenced using standard Sanger dye 
chain-termination sequencing through the services of MWG Operon (Huntsville, AL) 
using forward and reverse primers (Table 2.2) to read both template and coding strands. 
Sequencing reads were compared to publically available sequences of S. aureus N315 
(NCBI) by pairwise alignment. Target site modifications were recorded and annotated 
according to genomic position.  
 
Selection for resistance to sodium salicylate  
Spontaneous selection 
 An overnight culture of S. aureus strain SH1000, LAC and E. coli strain MG1655 
(K-12) was prepared under standard conditions. Large TSA plates (100 x 200 mm) as 
well as TSA gradient plates were prepared at ¼, ½, 1, 2, 3, 4, 5, 6 X MIC of either 
salicylate or acetyl salicylic acid. Cultures (100 µl) were inoculated onto each of the 
plates incubated at 37°C, and putative resistant colonies were selected after 24 h. 
Colonies were then passaged twice in the absence of NSAID before MICs were 
performed to determine if the recovered isolates had a higher level of resistance to the 
NSAID when compared to WT. 
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N-methyl-N-nitro-N-nitrosoguanidine (NTG)-mutagenesis       
To select for a salicylate resistant straing NTG mutagenesis was used. A single 
colony of S. aureus SH1000 was prepared under standard conditions. One milliliter of 
overnight culture was inoculated into 100 ml TSB and allowed to grow for 3 hours before 
addition of NTG (50 µg/ml final) or an equal volume of sterile water (control). Cell 
counts (CFU/ml) were performed immediately before addition of NTG. Cells were grown 
for 45 min with and without NTG before harvesting by centrifugation at 1,929 x g for 10 
min. NTG has been shown to induce at least one mutation per cell under the above 
growth conditions, which has been shown to correlate with a 50% survival rate [110]. 
NTG is known to add alkyl groups to O6 of guanine and O4 of thymine [110]. The 
supernatant of NTG-treated and non-treated (control) cultures was then removed and 
discarded, and the cells were resuspended in 100 ml of TSB by vortexing. These cells 
were then centrifuged again as before and the supernatant was discarded before being 
resuspended in 100 ml of TSB and allowed to grow for 2 hours. Cultures were then 
sampled to verify the efficiency of NTG killing, and serial dilutions were plated to 
determine final CFU/ml for NTG-treated compared to untreated cultures. Multiple 
libraries of NTG mutants were stocked by taking ten 1 ml aliquots in Eppendorf tubes 
and centrifuging them at 1,372 x g for 3 minutes. The supernatant was discarded and the 
cells were resuspended in TSB with 20% (v/v) glycerol and stored at -80°C.  
 
Stepwise selection 
 An overnight culture of S. aureus strain SH1000 was prepared under standard 
conditions. Cells were inoculated in fresh TSB at 1:100 containing 1.5 mg/ml salicylate. 
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The following day cells were plated on to TSA plates for cell counts and were also 
inoculated into fresh TSB at 1:100 containing 2X the initial concentration of salicylate. 
This process was repeated until no growth was recovered on TSA plates. MICs were 
determined for all colonies recovered following passage in TSB without antibiotic to 
determine if any of the cells acquired a higher level of resistance.  
 
2.3 Results 
Antibiotic specificity of the salicylate-associated genotypic resistance phenotype 
Salicylate-associated genotypic antibiotic resistance (SAGAR) has been described 
for the fluoroquinolone antibiotics ciprofloxacin and norfloxacin, as well as the steroid 
antibiotic fusidic acid in both laboratory and MDR strains of S. aureus. To further assess 
the scope of this phenotype, the impact of salicylate on the frequency of resistance to a 
spectrum of antibiotics belonging to several drug classes was investigated for S. aureus 
laboratory strain SH1000, and when possible, the CA-MRSA strain LAC (Table 2.1). Of 
the nine antibiotics tested, salicylate was observed to only alter the frequency at which 
resistance to ciprofloxacin (CipR), norfloxacin (NorR) and lincomycin (LinR) occurred 
(Table 2.3). The frequency at which CipR occurred in SH1000 increased by 27-fold 
(p=0.03) in the presence of salicylate (Table 2.3). The frequency at which CipR mutants 
in strain LAC occurred with salicylate also increased, but only by 6.2-fold and not 
significantly. Growth of SH1000 with salicylate also significantly increased the mutation 
frequency to NorR by 4-fold (p=0.01). Unlike ciprofloxacin and norfloxacin, the 
frequency at which resistance to lincomycin occurred with salicylate decreased by 3-fold 
in SH1000, but not significantly (p=0.05). Mutation frequency to norfloxacin and 
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lincomycin resistance for strain LAC was not determined, due to its high intrinsic 
resistance to these antibiotics; MICs for ciprofloxacin and lincomycin in LAC were 64 
µg/ml and an MIC of 25 µg/ml, respectively.  
To determine the effect of adapting S. aureus to salicylate on the SAGAR 
phenotype, cultures were grown overnight with salicylate (adaptive environment) or 
without (un-adapted) and then tested for SAGAR on plates, which contained 
ciprofloxacin alone, or ciprofloxacin and salicylate. Adaptation to salicylate did not 
influence the frequency at which CipR colonies occurred compared to un-adapted cultures 
when selected on ciprofloxacin plates without salicylate (Fig. 2.1). Also, adaptation to 
salicylate had no effect on the increase in frequency to CipR observed when selected in 
the presence of salicylate. Collectively, these findings reveal that the SAGAR phenotype 
is antibiotic specific. Furthermore, the results suggest that salicylate is not a chemical 
mutagen in S. aureus, agreeing with previous studies in Salmonella typhimurium [28], 
and reveals that adaptation of cultures to salicylate has no apparent impact on SAGAR.  
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Table 2.3. Antibiotic specificity of salicylate-associated genotypic phenotype. 
 
Antibiotic Strain Plated (µg/ml) 
Mutation Frequency 
Fold 
change SD Antibiotic 
(Abx) 
Abx + 500 
µg 
Salicylate 
Ciprofloxacin 
SH1000 1 4.9 X 10-8 8.5 X 10-7 27* 2.9 X 10-7 
SaRNH-1 1 5.2 X 10-7 2.1 X10-6 8.5* 6.9 X 10-7 
LAC 
Newman 
SaRNH-2 
16 
1 
1 
8.2 X 10-4 
3.2 X 10-6 
3.8 X 10-6 
2.4 X 10-3 
4.7 X 10-6 
4.3 X 10-6 
6.2 
1.5 
1.1 
3.6 X 10-3 
1.2 X 10-6 
1.8 X 10-6 
Fusidic Acid 
SH1000 0.5 6.1 X 10-7 8.7 X 10-7 1.4 6.0 X 10-7 
SaRNH-1 2 3.6 X 10-6 3.2 X 10-6 0.9 2.4 X 10-6 
LAC 4 7.7 X 10-8 1.6 X 10-7 2.2 1.2 X 10-7 
Lincomycin SH1000 1 3.4 X10 
-7 1.3 X 10-7 0.4* 1.0 X 10 -7 
SaRNH-1 1 1.2 X 10-7 1.2 X 10-9 0.02* 5.9 X 10 -10 
Norfloxacin 
SH1000 4 1.5 X 10-7 6.6 X 10-7 5.2* 2.6 X 10-7 
SaRNH-1 
Newman 
SaRNH-2 
4 
2 
2 
6.8 X 10-8 
2.1 X 10-6 
2.7 X 10-6 
6.9 X 10-7 
4.6 X 10-6 
4.3 X 10-6 
7.2 
2.8 
1.6 
6.7 X 10-7 
1.6 X 10-6 
1.3 X 10-6 
Rifampin 
SH1000 1 2.9 X 10-7 2.3 X 10 -7 0.8 1.4 X 10-7 
SaRNH-1 1 6.2 X 10-8 6.3 X 10-8 1 3.1 X 10-8 
LAC 0.1 9.8 X 10-8 1.2 X 10-7 1.7 8.6 X 10-8 
Tetracycline SH1000 0.5 5.6 X 10
-7 1.0 X 10-6 2 3.8 X 10-7 
SaRNH-1 190 4.5 X 10-6 7.0 X 10-6 1.9 1.7 X 10-6 
Vancomycin SH100 3 5.7 X 10
-6 2.3 X 10-6 0.3 3.0 X 10-6 
LAC 7 6.43 X 10-8 2.6 X 10 -8 0.4 1.9 X 10-8 
 
SD indicates standard deviation for mutation frequency with antibiotic (abx) with 
salicylate. Asterisks denotes statistical significance p< 0.05, n=3. Strains were plated at 1 
or 2X the MIC.  
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Figure 2.1. Frequency of resistance to ciprofloxacin in S. aureus cultures adapted to 
salicylate. CFU/ml of CipR colonies of SH1000 are plotted as a function of treatment: 
growth overnight with salicylate (adaptive environment) or without (control, non 
adaptive) and then plated to ciprofloxacin alone (filled bars) or ciprofloxacin and 
salicylate (hatched bars). Asterisks denote statistical significance by ANOVA and 
Tukey’s HSD (p= 0.01).  
 
 
Antibiotic specificity of the SAGAR phenotype 
Broth microdilution minimum inhibitory concentration (MIC) assays were used to 
determine if selection for resistance to antibiotics with salicylate conferred the same level 
of resistance as selection in the absence of salicylate. MICs for antibiotic resistant 
isolates of strains SH1000, SaRNH-1 (a.k.a. SH1000sigB::tet), and LAC exceeded 
clinical and laboratory standards institute (CLSI) breakpoints for all drugs, except for 
lincomycin (breakpoint = 10 µg/ml) and vancomycin (breakpoint = 16 µg/ml) (Table 
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2.4). MICs for ciprofloxacin did not differ for resistant isolates selected with or without 
salicylate, but were lower for fusidic acid, lincomycin and norfloxacin resistant isolates 
for all strains when selected in the presence of salicylate (Table 2.4). MICs for SaRNH-1 
resistant isolates did not differ between MICs for SH1000 resistant isolate strains for 
ciprofloxacin. Interestingly, a difference in the level of resistance between resistant 
isolates was observed. For example SaRNH-1 lincomycin isolates selected in the absence 
of salicylate had higher MICs (4 µg/ml) than SaRNH-1 lincomycin isolates selected in 
the presence of salicylate with an MIC of 2 µg/ml, These results suggest that the 
mutations, which lead to resistance to some antibiotics when selected in the presence of 
salicylate, may differ from those that lead to resistance in the absence of salicylate. Also, 
a difference in colony morphology was observed. Small colonies like variants were 
observed on antibiotic plates selected in the presence and absence of salicylate.  
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Table 2.4. Minimum inhibitory concentrations (MICs) for antibiotic resistant 
isolates selected with or without salicylate  
 
Drug Strain 
Initial  
MIC 
(µg/ml) 
                 MICs (µg/ml) 
        Sal -                             Sal + 
LC SCV LC* SCV* 
Ciprofloxacin 
SH1000 0.5 4 4 4 4 
SaRNH-1 1 4 4 4 1 
LAC 64 512 512 124.3 124.3 
Fusidic Acid 
SH1000 0.24 124.8 124.8 124.8 124.8 
SaRNH-1 0.98 NP NP NP NP 
LAC 0.24 249.8 124.9 NP NP 
Lincomycin SH1000 1 4 4 4 4 
SaRNH-1 1 4 4 2 2 
Norfloxacin SH1000 2 16 16 8 4 
SaRNH-1 4 32 16 16 8 
Rifampin 
SH1000 0.25 NP NP NP NP 
SaRNH-1 0.5 NP NP NP NP 
LAC 0.02 NP NP NP NP 
Tetracycline SH1000 1 4 1 4 1 
SaRNH-1 64 NP NP NP NP 
Vancomycin SH100 1 4 4 4 4 
LAC 3 NP NP NP NP 
  
All values are in micrograms per milliliter.  
Large colony variant (LC); small colony variant (SC). 
NP denotes not performed. 
Sal  denotes salicylate at 500 µg/ml  
 
Characterization of mutations conferring resistance to fluoroquinolones  
Quinolone resistance is gained through modification of gyrAB and grlAB targets 
as well as modification through the norA efflux pump promoter sequence, which are 
associated with clinical levels of resistance [111-114]. A difference in the level of 
quinolone resistance in some strains selected for in the presence or absence of salicylate 
was detected. It was of interest to sequence gyrAB and grlAB quinolone resistance 
determining region (QRDR) to determine if there was a difference between the acquired 
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SNPs. All mutations conferring resistance to ciprofloxacin and norfloxacin were 
determined to be in a 347-bp region of grlA, encoding the A subunit of topoisomerase IV. 
This resulted in a common mutation at amino acid Ser80 [113, 115], as well as less 
common (or unreported) mutations at Arg43 and Ala115 (Table 2.5). The location of the 
SNP had no apparent effect on the level of ciprofloxacin resistance, MIC = 4 µg/ml 
(Table 2.4). However, for norfloxacin resistant large colony (LC) isolates, the location of 
the SNP did not differ, but the level of resistance did: MIC of 16 µg/ml (without 
salicylate) and 8 µg/ml (with salicylate) (Table 2.4 and 2.5). Lincomycin, a macrolide, 
acts on the 50S ribosomal subunit, specifically targeting 23S rRNA [116]. Macrolides, 
such as erythromycin have been shown to target A2058G/U or A2059G, however, the 
exact mutation responsible for conferring lincomycin resistance remains to be identified 
[117]. Therefore, target site modifications conferring resistance to lincomycin were not 
determined. 
 
 
Table 2.5. Sequencing results for grlA in fluoroquinolone resistant isolates in 
SH1000 compared to NCBI  S. aureus sp N315. 
   
SH1000 Antibiotic Original SNP Genomic Mutation Original AA Location Location 
LC 
Cipro 
A G 1,356,325 His Arg 43 
LC* C T 1,356,564 Phe Ser 80 
LC C G 1,356,671 Ala Ala 115 
LC, LC* Nor C T 1,356,564 Phe Ser 80 SCV C T 1,356,672 Val Ala 115 
 
Large colony variant (LC); small colony variant (SC). 
Selection for antibiotic resistance in the presence of salicylate denoted by *. 
Single nucleotide polymorphism (SNP). 
Amino acid location (AA location). 
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Role of sigB and mgrA in the SAGAR phenotype 
Alternative sigma factor B (σB) directs the transcription of more than one hundred 
genes in response to different stressors [98, 118]. Sigma factor B is necessary for full 
expression of salicylate-inducible phenotypic resistance, and its expression was shown to 
be upregulated upon salicylate exposure [71, 74]. MgrA is a helix-turn-helix DNA 
binding protein and, like SigB, regulates many S. aureus genes (approx. 355) [66] 
including genes shown to control autolytic activity and the expression of several 
virulence factors, including alpha-toxin, nuclease and protein A [66]. Importantly, MgrA 
negatively regulates the multiple drug efflux pumps NorA, NorB, NorC, Tet38 and 
AbcA, shown to be important for resistance to fluoroquinolones [75, 76], and mgrA 
transcript levels are repressed by salicylate [71]. In previous studies, an mgrA mutant 
showed resistance to ciprofloxacin, which was linked to increased expression of norA 
[66, 70]. Since σB and MgrA contribute to the phenotypic resistance mechanism, we 
aimed to ascertain the role for these regulators in the SAGAR phenotype using strains, 
which are isogenic for either sigB or mgrA (Table 2.1).  
Removal of sigB in SH1000 (SH1000sigB::tet) did not significantly alter the 
mutation frequency in the absence of salicylate to ciprofloxacin (p=0.07), norfloxacin 
(p=0.43) or lincomycin (p=0.09) when compared to WT SH1000  (Table 2.3). However, 
removal of sigB significantly reduced the mutation frequency to ciprofloxacin with the 
addition of salicylate from 27-fold in SH1000 down to 8.5-fold in SH1000sigB::tet 
(p=0.02). Interestingly, the same effect was not seen with norfloxacin, where the 
mutation frequency in SH1000sigB::tet slightly but insignificantly increased to 7.2-fold 
compared to 5.2-fold in SH1000 (p=0.09). Although SAGAR was not observed for 
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lincomycin in SH1000, in SH1000sigB::tet salicylate decreased the mutation frequency 
to lincomycin by 0.02-fold (or a 50-fold reduction) (p=0.04). These findings emphasize a 
significant role for sigB in the salicylate associated genotypic antimicrobial resistance 
phenotype (SAGAR) phenotype. 
For mgrA analysis, S. aureus strain Newman [110], and its mgrA null derivative 
(Table 2.1) were used to assess the potential contribution of mgrA to the SAGAR 
phenotype. In Newman, salicylate was shown to slightly increase mutation frequency to 
ciprofloxacin and norfloxacin (p=0.02 and p=0.01, respectively). However, the increase 
in ciprofloxacin mutation frequency was less than that observed for strains SH1000 or 
LAC (Table 2.3). Deletion of mgrA in the Newman background did not significantly alter 
mutation frequency in the presence of salicylate for ciprofloxacin (p=0.10) and 
norfloxacin (p=0.07) (Fig. 2.2). Although we did not observe a significant change in 
mutation frequency upon deletion of mgrA in the Newman background, we cannot rule 
out a potential role for mgrA in SH1000 as our results have indicated strain specificity for 
SAGAR.  
 
Investigating the chemical signature associated with salicylate associated genotypic 
resistance to antibiotics 
Salicylate-inducible phenotypic resistance to fluoroquinolones has been attributed 
to the carboxylic acid group of salicylate and acetyl salicylic acid [33], however the 
importance of this functional group, and others intrinsic to salicylate in SAGAR, is 
unknown. To identify chemical features of salicylate that contribute to SAGAR, the 
effect of the salicylate analogs sodium benzoate (weak acid) and acetylsalicylic acid 
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(NSAID) (Fig. 2.2) on mutation frequency to ciprofloxacin, norfloxacin and lincomycin 
resistance was determined.  
Mutation frequency to ciprofloxacin resistance was significantly higher with 
salicylate when compared to sodium benzoate, acetylsalicylic acid (ASA), and controls 
(p=0.03) (Fig. 2.3). Benzoate and ASA differ structurally at the ortho position, the 
hydroxyl group of salicylate being reduced to hydrogen at this position in benzoate, 
whereas in ASA, this hydroxyl group is acetylated (Fig. 2.2). For lincomycin, a 
significant decrease in mutation frequency was observed for benzoate, salicylate, and 
ASA when compared to untreated cultures (p<0.05), but not between treatments (Fig. 
2.3). Similarly, for norfloxacin, there was no significant difference in the mutation 
frequency of SH1000 to ciprofloxacin with salicylate when compared to benzoate, or 
salicylate compared to ASA, or benzoate to ASA (p=0.07, p=0.06, and p=0.05, 
respectively). Our results indicate that salicylate is needed to fully propagate the SAGAR 
phenotype for ciprofloxacin and norfloxacin.  
 
 
 
 
 
Figure 2.2. Structural differences between salicylate, benzoate and acetyl salicylic 
acid. Box indicates altered chemistry at the ortho-position. 
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Figure 2.3. Dependence on salicylate chemical structure for SAGAR. Fold change in 
frequency of resistance to antibiotics determined for cultures selected in the presence of 
salicylate (black), benzoate (hatched), and acetyl salicylic acid (dotted). Error bars 
indicate standard deviation of the mean, and asterisks denote groups that differ 
significantly by ANOVA and Tukey’s HSD (a=0.05, n=3).  
 
2.4 Discussion 
  The results of this study revealed that the SAGAR phenotype for salicylate is drug 
specific. The salicylate associated antibiotic resistance (SAGAR) phenotype was only 
observed for the fluoroquinolones, ciprofloxacin and norfloxacin, in strain SH1000. The 
phenotype was more prominent with ciprofloxacin than with norfloxacin. This suggests 
that SAGAR is highly selective and sensitive to subtle changes in antibiotic structure. 
Ciprofloxacin and norfloxacin are structurally very similar in that both have fluorinated 
quinoloic acid cores; however there are differences. For example, ciprofloxacin has a 
cyclopropane ring at the N-1 position, while norfloxacin has an ethyl group at the same 
position [119]. In addition, studies by Chin et al. [120] found that ciprofloxacin was 4 to 
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32 times more active than norfloxacin. They proposed that the cyclopropane ring that 
ciprofloxacin possesses is able to alter the DNA gyrase activity, rendering it more 
efficient [120]. 
   Ciprofloxacin resistance is a highly common occurrence in S. aureus strains [91, 
121, 122], as such it is not indicated for infections and the clinical ramifications of 
SAGAR in S. aureus are currently benign. Quinolones, however, are the primary 
treatment option for urinary tract infections caused by Escherichia coli [123]. Despite the 
similarity in the quinolone resistance mechanism, this SAGAR phenotype has yet to be 
reported in other bacteria besides S. aureus. In order to determine the mechanism 
responsible for this SAGAR, and the significance of the structure of ciprofloxacin to the 
phenotype, more quinolones/fluoroquinolones need to be tested. Studying other bacterial 
species in which quinolones are still being used for therapeutic treatments can also 
further elucidate the mechanism.  
Ciprofloxacin is associated with DNA damage, specifically through double 
stranded DNA breaks and stalled replication forks, which are processed to single-
stranded DNA [88]. Looking at the global transcriptional response to ciprofloxacin 
treatment by Cirz et al. [88] revealed induction of Pol III and Y-family polymerases, 
which emphasizes a common strategy of reduced metabolism and funneling of resources 
into DNA synthesis in response to these antibiotics. It is also believed that DNA 
synthesis might be error prone due to the down-regulation of mismatch repair genes 
during exposure to ciprofloxacin [124, 125]. Therefore, it is possible that salicylate, when 
coupled with ciprofloxacin, exacerbates this effect, which may explain the drug 
specificity of SAGAR.  
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  Through DNA sequencing of the ciprofloxacin targets, grlAB and gyrAB, our 
results revealed mutations only in the QRDR domain of grlA. No difference in the level 
of ciprofloxacin resistance was observed between LC and SCV colonies selected in the 
presence or absence of salicylate. However, for norfloxacin, a higher level of resistance 
was observed between LC selected in the absence of salicylate than those selected in the 
presence of salicylate. This indicates a mutation outside of the grlA QRDR in the 
salicylate treated colony that is accounting for this slightly decreased level of norfloxacin 
resistance. Determining the exact mutation responsible for this difference is not practical 
without resorting to whole genome sequencing [126-128]. 
  S. aureus has been shown to result in heterogeneous expression of resistance to 
various antibiotics [133, 57, and 134]. For example, heterogeneous intermediate 
resistance to vancomycin (hVISA) is attributed to several genes related to cell regulation 
pathways including vraSR, graSR saeSR, and agr [129-132]. A similar heterogeneity has 
been observed by Price et al. [26] for salicylate inducible phenotypic resistance to fusidic 
acid. The level of fusidic acid resistance induced by salicylate was found to be dependent 
upon the genetic background of the strain.  
  It was thus no surprise when this study revealed that the SAGAR phenotype was 
strain specific. Expression of SAGAR varied substantially between strains in this study, 
as well as in previous studies for ciprofloxacin, ranging from a 8-fold to a 100-fold 
increase in mutation frequency [33]. This variation likely reflects the inherent genetic 
variation among these S. aureus strains and suggests that there are unknown genetic 
factors important for this phenotype.  
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  One of the genetic factors important for this heritable phenotype is likely to be σB, 
as mutation of sigB significantly reduced expression of SAGAR for ciprofloxacin. σB 
plays a prominent role in the cell, controlling roughly 198 genes [79], many of which are 
involved in resistance to stressors [133]. σB has also been shown to be involved in the 
repression of exoproteins and toxins, and is a positive regulator of adhesion factors [79, 
80, 103, 133]. More importantly, σB is believed to play a role in mediating antibiotic 
resistance [79]. Inactivation of sigB in MRSA-COL was found to increase its 
susceptibility to methicillin [98] while mutations within the rsbU-defective strain BB255, 
leading to SigB hyperproduction, were associated with an increase in glycopeptide 
resistance [134]. σB has been shown under stress, to upregulate genes responsible for 
maintaining cell integrity, membrane transport processes and intermediary metabolism 
[118]. Thus, it is possible that salicylate in σB null strains is able to permeate the cell 
more readily, allowing more salicylate to enter the cell, further enhancing its toxicity and 
mitigating SAGAR.  
  S. aureus BB255, a ciprofloxacin sensitive strain carrying an 11-bp deletion in rsbU 
encoding a positive regulator of σB [33, 135, 136], demonstrated a 100-fold increase in 
mutation frequency to ciprofloxacin with salicylate [33]. SH1000 differs from BB255 in 
that SH1000 is rsbU+, and has increased pigmentation, more vigorous growth, decreased 
secreted exoproteins and decreased agr expression. Thus, perhaps differences in SAGAR 
for ciprofloxacin between strains reflect differences in sigma B activity. However, the 
frequency of mutation to ciprofloxacin resistance for SaRNH-1 (SH1000sigB::tet) was 
actually less than 50% of that observed for SH1000, and less than 10% that of BB255. 
Despite the 11-bp deletion in the rsbU gene, researchers have shown salicylic acid to 
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activate σB in both rsbU+ and rsbU null strains [137]. Therefore, it is possible that σB 
positively influences SAGAR while rsbU negatively influences SAGAR. Our results 
indicate σB dependence for full expression of the SAGAR phenotype.  
  The use of salicylate analogs to investigate the importance of chemical structure in 
the phenotype revealed the importance of the ortho-hydroxyl group of salicylate. Sodium 
benzoate lacks this hydroxyl group, while acetylsalicylic acid has an acetyl group in the 
ortho position. Removal of the hydroxyl group mitigated SAGAR for both ciprofloxacin 
and norfloxacin. While for lincomycin removal of the hydroxyl group (i.e. by use of the 
structural analog benzoate) potentiated the effect salicylate had on reducing the 
frequency at which resistance occurred. Interestingly, the reactive group of salicylate for 
inducing oxidative stress in mitochondria has been shown to be this hydroxyl group 
[138], which is believed to interact with a Fe-S cluster of mitochondrial Complex I 
resulting in the production of ROS [14, 15, 82, 138]. A structural dependence was also 
observed for salicylate-inducible phenotypic resistance to ciprofloxacin [33]. However, 
the functional group was determined to be the carboxylic acid [33], which suggests a 
potential mechanistic distinction between inducible phenotypic resistance and SAGAR. 
The results suggest that this hydroxyl group is important for SAGAR, which could 
possibly lead to ROS accumulation. This ROS accumulation could result in DNA 
damage, which could explain the increase in mutation frequency. 
  Finally, our results indicate both inducible phenotypic resistance (data not shown) 
and SAGAR require the presence of salicylate in the media for the phenotype, which 
suggests a mechanistic link. It is possible that salicylate has a physiochemical effect on 
the cell which leads to metabolic toxicity or that salicylate is a ligand for a yet to be 
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determined protein which can both affect antibiotic permeability results in interference 
with DNA repair mechanisms.   
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CHAPTER THREE: 
 ROLE FOR METABOLIC STRESS IN THE SALICYLATE-ASSOCIATED 
ANTIBIOTIC RESISTANCE PHENOTYPE 
 
3.1 Background  
  Metabolic alterations play an important role in resistance of bacteria to 
antimicrobials [139]. Changes in growth rate have been shown to influence bacterial 
susceptibility to antibiotics [139]. For example, metabolically moribund E. coli have been 
shown to be highly resistant to ampicillin or tetracycline, and many antibiotics have 
reduced activity against stationary phase cultures [140]. Also, changes in bacterial 
metabolism, such as those associated with dormancy or biofilm formation, are associated 
with reduced susceptibility to antibiotics [141]. Alterations in metabolism in response to 
antimicrobials have been also linked to small colony variant (SCV) formation in S. 
aureus [142]. SCVs display a decreased rate of cell wall biosynthesis, a reduction in the 
uptake of positively charged antimicrobials and an increase in survival in host cells [142]. 
These reductions are associated with a 4-fold increase in MICs to cell wall targeting 
antibiotics [142].  
  Growth with salicylate induces phenotypic resistance to antimicrobials, and 
increases the frequency at which genotypic resistance (SAGAR phenotype) to some 
antibiotics occurs in S. aureus [7, 26, 33, 43, 70, 71]. These phenotypes occur at 
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concentrations of salicylate which are subinhibitory, but which are still toxic to growth. 
Previous studies revealed substantial alterations in the transcript levels of genes 
associated with central metabolism during growth with sub-MIC levels of salicylate [43]. 
Specifically, salicylate reduced the expression of genes important for 
glycolysis/gluconeognesis such as gapA2 (encoding GAPDH) and pgi (glucose-6-
phosphate isomerase). In addition, salicylate increased expression of genes for gluconate 
metabolism via the pentose phosphate shunt. This indicates that growth with salicylate at 
concentrations that induce phenotypic resistance, and which are associated with SAGAR, 
may inhibit glycolysis and increase gluconate metabolism [43]. Furthermore, these 
findings suggest that S. aureus may alter flux through metabolic pathways to counter the 
toxic effects of salicylate. In support of this claim, growth with gluconate was shown to 
rescue the cell from the toxic effects of salicylate on growth [43]. Salicylate has been 
shown to also result in ROS accumulation and DNA damage in eukaryotic models [5, 7, 
82]. Specifically, salicylates have damaging effects on isolated mitochondria and have 
been shown to result in uncoupling of oxidative phosphorylation as well as swelling 
[138]. It is possible that salicylate has the same DNA damaging effects which can 
ultimately lead to this increase in mutation frequency; i.e SAGAR. Collectively, these 
studies reveal that salicylate may act at several levels to negatively impact metabolism in 
the cell. The importance of these metabolic alterations in the presence of salicylate to 
antibiotic resistance in S. aureus is currently unknown. The following experiments were 
designed to examine the link between the metabolic toxicity of salicylate and the 
SAGAR phenotype. 
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3.2 Methods 
Generation Time Determination 
The following protocol was adapted from Neoh et al.[132]. An overnight culture 
of strain SH1000 was prepared under standard conditions before being subcultured into 
fresh TSB to an optical density at 600 nm OD600=0.05. Optical density readings were 
recorded from an OD600=0.05 to an OD600=0.5. Cells were treated with increasing 
concentrations of NSAID, a weak acid, or for controls, an equal volume of water (or 
respective solvent used for stocking NSAIDs/weak acids). Samples or plate counts 
(CFU/ml) were taken every 30 min. Generation times were determined using Eq. 3.1 
(below), where g is generation time, N1 is optical density at which the last reading was 
taken, N0 is the initial optical density taken and t1 is the time in minutes from the initial 
reading (t0)) to reach an optical density of 0.5. Data was analyzed using a t-test to identify 
statistically significant differences between controls and treatment.  
 
Eq. 3.1: g = !"# !"!#!!!!!  
 
 
Mutation frequency determination 
 The following protocol was adapted from Foster, 2006 [108]. This protocol is 
identical to that of Chapter 2 Methods, section 2.2, except that mutation frequency to the 
antibiotic was determined over a range of NSAID and weak acid concentrations. For 
mutation frequency determinations under anaerobic conditions, cultures were grown in 
anaerobic chambers with CO2 packs (EZ container system, Becton, Dickson and 
company) and incubated at 37°C.  
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Metabolite profiling 
The following protocol was adapted from Meyer et al. 2010 [143]. Overnight 
cultures (n=3) of S. aureus strain SH1000 were prepared under standard conditions. The 
following day the culture was inoculated into 100 ml fresh TSB at OD600=0.05. This 
culture was grown at 37°C at 448 x g until an OD600=0.5 was reached. At this point either 
500 µg/ml or 2500 µg/ml of salicylate was added to the experimental flask or the 
equivalent volume of water was added to the control flask and cultured for 30 min. From 
each flask, 20 ml of culture was extracted and then filtered through a 0.22 µm Millipore 
filter. Cells were then washed twice with 10 ml cold 0.6 % (wt/vol) NaCl. The filter was 
then cut out and placed into a corning tube containing 10 ml of ice cold 60% (vol/vol) 
ethanol. The corning tubes were vortexed for 10 minutes to ensure that all the cells came 
off the filter. The filter was then discarded and the corning tubes were stored in the -80°C 
freezer for an hour. Cells were then thawed on ice, while being rigorously mixed and 
shaken 10 times alternately. Aliquots of 1 ml cell suspensions were transferred into an 
appropriate number of tubes containing 0.5 cm3 glass beads (diameter 0.10-0.11 mm). 
Cells were disrupted for 2 cycles for 30 seconds at 5,179 x g in a bead-mill (Mini-bead 
beater, Biospec). After cell disruption the glass beads and the cell debris were separated 
from the supernatant by centrifugation for 5 min at 4°C and 10,000 x g. The aliquoted 
samples were combined, and the glass beads were washed once with 1 ml ddH2O each. 
Washing entailed vortexing of the beads in the water and centrifugation for 5 min at 4°C 
and 10,015 x g. The washing solutions were added to the combined samples. The 
supernatant including the metabolites were brought to a final ethanol concentration of 10 
% (vol/vol) and stored at -80°C. The metabolites were shipped on dry ice to the 
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University of Illinois for analysis. The metabolites were analyzed separated by liquid and 
gas chromatography and analyzed by mass spectrometry at the Metabolomics Center, 
Roy J. Carver Biotechnology Center, University of Illinois at Urbana-Champaign 
(http://www.biotech.uiuc.edu/centers/MetabolomicsCenter/index.html). 
 
Analysis of intracellular metabolites 
 Metabolite peaks were identified by comparison to a spectrum generated from 
standards. The means and standard deviation were calculated for each treatment. An 
ANOVA was performed comparing 0 µg/ml, 500 µg/ml and 2500 µg/ml salicylate 
(a=0.05, n=3). A 2- fold change was used as a cutoff for biological significance. Those in 
which statistics and biological significance were satisfied were further characterized 
based on metabolic pathway. The online software Metaboanalyst was used to identify 
pathways (http://www.metaboanalyst.ca/MetaboAnalyst/faces/Home.jsp).  
 
Reactive oxygen species assay (ROS) 
  ROS was measured using luminol and DCFH-DA. Overnight cultures of S. 
aureus strain SH1000 (n=3) were prepared under standard conditions. The following day 
the culture was diluted into fresh TSB at a 1:100 to obtain OD600=0.05. The culture was 
allowed to grow in a shaking incubator at 37°C at 448 x g to an OD=0.5. The appropriate 
volumes of salicylate were added to obtain a final concentration of 500 and 2500 µg/ml. 
These treatments served as the experimental conditions. Carbonyl cyanide m-
chlorophenylhydrazone (CCCP) was added to a final concentration of 100 µM, which 
served as a positive control, and glycerol at 0.4% (vol/vol) as a negative control. An 
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additional treatment, which included only cells grown in TSB, served as a control for 
basal ROS levels. Cells were exposed to each treatment for a total of 24 hours, and 
readings were taken at 0.5 h, 3 h, 8 h, and 24 h. At each time point 1 ml of culture was 
placed into a 1.5 ml microtube and centrifuged at 2,500 x g for 15 min. The supernatant 
was decanted and the cells were resuspended in 500 µl of phosphate buffered saline 
(PBS, pH 7.1).  
For DCFH-DA, the following protocol was adapted from OxiSelect ROS Kit 
(Cell Bio Labs, California) and performed per the manufacturer’s instructions. To each 
sample, 2’,7’-dichlorﬂuorescein-diacetate (DCFH-DA) was added to a final 
concentration of 10 µM. The samples were vortexed and incubated in the dark at 37°C 
for 5 minutes. From each tube, 100 µl was added in triplicates to a 96 well plate. Luminol 
was used for ROS detection following previously described methods (Chen et al. 2011). 
Briefly, for each treatment, 100 µl of the prepared sample was added in triplicate to a 96 
well plate. To each prepared well 100 µl of 250 µM luminol was then added. A synergy2 
plate reader with Gen5 software (BioTek, Vermont) was used to record fluorescence. 
Fluorescence was recorded at 460/40 emission and 360/40 excitation. The following 
protocol was performed with a sample size of 3. Optical density for each treatment at 
each time interval was recorded. Relative fluorescence units recorded were adjusted to 
OD. Statistical significance between treatments was compared using an ANOVA 
(a=0.05, n=3) (R ver 2.13.0). 
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NAD+/NADH Assay 
 To conduct a standard curve for NADH/NAD quantitation, 10 µl of a 1 nmol/µl 
NADH standard (Biovision, California) was diluted with 990 µl NADH/NAD Extraction 
Buffer to generate 10 pmol/µl standard NADH. Of the diluted NADH standard, 0, 2, 4, 6, 
8, 10 µl were added into labeled 96-well plate in duplicates, resulting in a dilution series 
of 0, 20, 40, 60, 80, 100 pmol/well. The final volume was adjusted to 50 µl with 
NADH/NAD extraction buffer (Biovision). Readings were taken using a plate reader at 
OD450. The standard curve was analyzed for strength of linearity by regression analysis 
(R). For NADH/NAD quantitation, an overnight culture was prepared in TSB with S. 
aureus strain SH1000. The following day 1 ml of cells was washed with 500 µl cold PBS 
and pelleted at 448 x g for 5 min. To each sample, 400 µl of NADH/NAD extraction 
buffer was added followed by two cycles of freeze/thaw (20 min at -80°C, then 10 min 
room temperature). The cells and buffer were then vortexed for 10 sec and pelleted at 
21,952 x g for 5 min. The extracted NADH/NAD supernatant was transferred into a 
labeled tube. This was performed before addition of salicylate or CCCP, and 3 h 
following addition of 1 µg ciprofloxacin, 500 µg/ml salicylate, 2500 µg/ml salicylate or 
an equal volume of water (control). 
To detect total NAD (NAD+ + NADH) 50 µl of the extracted samples were 
transferred into a 96-well plate in duplicates. An NAD cycling mix was prepared for each 
reaction by adding 100 µl of NAD cycling buffer and 2 µl of NAD cycling enzyme mix. 
One hundred microliters of the NAD cycling mix was added to each well and incubated 
at room temperature for 5 min. Ten microliters of NADH developer was added to each 
well and incubated at room temperature for 1 hr. Readings were taken using a plate 
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reader at OD450. NADH was detected by adding 200 µl of the extracted samples into 
Eppendorf tubes. The samples were then heated to 60°C for 30 min. This step 
decomposed all NAD+. The samples were then cooled on ice and vortexed to remove 
precipitates. Fifty microliters of the NAD+ decomposed samples were transferred into 96-
well plates in duplicates. One hundred microliters of the NAD cycling mix was added to 
each well and incubated at room temperature for 5 min. Ten microliters of NADH 
developer was added to each well and incubated at room temperature for 1 hr. Readings 
were taken using a plate reader at OD450. Statistical significance was determined between 
treatments using an ANOVA (a=0.05, n=3) (R ver 2.13.0). The sample readings were 
applied to the NADH standard curve with the following equation X=(Y+0.0527)/0.3071. 
The amount of NAD+ or NADH in the sample wells were calculated then divided by 
OD600 of the culture prior to extraction.  
 
Eq3.2: NAD/NADH Ration is calculates as:  
 
 
3.3 Results 
Dose-dependence of salicylate-associated genotypic antibiotic resistance 
To determine the relationship between salicylate, sodium benzoate, and 
acetylsalicylic acid growth toxicity and the salicylate associated genotypic antibiotic 
resistance  (SAGAR) phenotype, generation time (g) and mutation frequency (µ) were 
calculated for a wide range of salicylate, sodium benzoate, and acetylsalicylic acid 
concentrations. Salicylate was only shown to significantly impair growth at 2500 µg/ml, 
NADtotal-NADH 
NADH
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increasing g from 29.7 to 48.8 min  (p=0.002) (Fig. 3.1A). For Asa, this was slightly less 
at 2000 µg/ml, increasing g to 54 min (p=0.002) (Fig. 3.1C), and benzoate was the least 
growth toxic, requiring 5000 ug/ml to significantly inhibit growth, increasing g to 45.7 
min (p=0.012) (Fig. 3.1E). 
For Sal, Asa, and Ben, SAGAR was determined to be concentration-dependent, 
and only occurred at non-growth-toxic concentrations. For Sal, SAGAR was observed at 
50-1000 ug/ml, but was absent at 2500 ug/ml (Fig. 3.1B). Likewise, for Asa and Ben 
SAGAR was observed at 50-500 µg/ml and 50-1000 ug/ml, but absent at 2000 µg/ml and 
5000 µg/ml, respectively (Fig 3.1 D and F). Thus, the expression of the SAGAR 
phenotype is suppressed at growth-toxic concentrations of Sal, Asa and Ben. 
 
 
 
 
 
 
 
 
 
 
	   	  43	  
 
Figure 3.1. Dose dependency of salicylate, aspirin, and benzoate for increased frequency of 
resistance to ciprofloxacin. Generation time of SH1000 as a function of increasing 
concentrations of salicylate (panel A), aspirin (panel C) and benzoate (panel E). (B) Mutation 
frequency of SH1000 to ciprofloxacin resistance plotted against an increasing concentration of 
salicylate (panel B), aspirin (panel D) and benzoate (panel E). Asterisks denote statistical 
significance using a t-test (*p<0.05). 
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Metabolite profile of S. aureus grown in the presence of salicylate 
 
To ascertain the metabolic alterations associated with salicylate exposure, 
metabolite profiling was performed for S. aureus strain SH1000 exposed to nontoxic 
(500 µg/ml) and growth-toxic (2500 µg/ml) concentrations of salicylate, which select for 
genotypic resistance, or are non-selective, respectively. Metabolite profiling revealed a 
total of 153 altered metabolites among the three treatments (Table 3.1). Of the 153 
altered metabolites 88 were less abundant, 3 had no change, and 44 were more abundant 
for the 2500 µg salicylate treatment compared to the control treatment. Also, 78 
metabolites were less abundant, 3 had no change, while 61 were more abundant for the 
500 µg/ml salicylate treatment compared to the control. Between the 2500 µg/ml and 500 
µg/ml salicylate treatments 82 metabolites were less abundant, 4 had no change and 53 
were more abundant for the 2500 µg/ml treatments when compared to the 500 µg/ml 
treatment.  
Metabolite profile revealed a decrease in TCA metabolites at the 500 µg/ml 
salicylate treatment, as seen through a reduction in citric acid (0.4-fold), acontic acid 
(0.2-fold), α-ketoglutaric acid, (0.4-fold) and fumaric acid (0.6-fold) in relation to non-
salicylate treated cultures, respectively (Table 3.1). A 2.1 fold accumulation of 2-
phosphoglycerate was also observed in the 500 µg/ml salicylate treatment when 
compared to the 2500 µg treatment (p=0.04) (Table 3.1). Previously a study by Riordan 
et al. 2007 [43] showed downregulation of gapA2 encoding a glyceraldehyde-3-
phosphate dehydrogenase, pgi encoding a glucose-6-phosphate isomerase, and 
SACOL1838 encoding a phosphoenolpyruvate carboxykinase. Each is indicative of 
reduction in glycolysis. Accumulation of 2-phosphoglycerates revealed further 
 
 
 
	   	  45	  
downregulation of glycolysis as this gene is involved in the final step of converting 
glucose to pyruvate. This is also corroborated in eukaryotic systems, specifically as seen 
in mitochondria [84]. A 8.8-fold increase in 2-ketogluconic acid compared to non-
salicylate treated cultures was observed at the 500 µg/ml treatment as well (p=0.023) 
(Table 3.1). The S. aureus gluconate operon gntRKP was shown to be upregulated with 
salicylate stress [43]. This increase in gluconate utilization gene expression may reflect 
an important metabolic alteration necessary to compensate for the growth inhibitory 
effects of salicylate. This effect on gluconate metabolism genes was also observed at the 
2500 µg/ml salicylate treatment (p=0.00019), with a 6.7-fold increase in levels compared 
to the non-salicylate treated treatment (Table 3.1). Interestingly, an accumulation of lactic 
acid was observed with salicylate treated cultures, which is indicative of anaerobic 
fermentation (p=0.035) [145]. In addition, butanediol increased by 4-fold in the presence 
of salicylate (Table 3.1). Lactic acid and butanediol production are used by S. aureus to 
cope with acid-stress [146], suggesting that perhaps growth with salicylate leads to 
acidification of the cytoplasm. For example, to avoid further acidification of an already 
acidic internal environment pyruvate is metabolized via acetolactate or the diacetyl 
pathway to butanediol. It is believed that S. aureus increases pH through accumulation of 
ammonium and through the removal of acid groups, which results in the production of 
2,3-butanediol [146]. Also, the accumulation of acid may aid in stress as lactic acid was 
initially synthesized from pyruvate, which can then be oxidized further by the TCA cycle 
[141]. 
Two important mechanisms for increasing pH in S. aureus cultures which are acid 
stressed is through the production of ammonia by urease and removal of acids [146]. An 
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increase in urea was observed in the presence of 500 µg/ml salicylate by 1.8-fold 
(P=0.0026) (Table 3.1). A dose dependent effect was observed between the 500 and 2500 
µg/ml treatments. Specifically, a 5-fold increase in uracil was observed at the 500 µg/ml 
treatment when compared to the 2500 µg/ml treatment indicating acid-stress. Also, 2-
phosphoglycerate was observed to be 2-fold higher at 500 µg/ml than 2500 µg/ml 
indicating impairment in glycolysis. Butanediol was 4-fold higher at the 2500 µg/ml 
treatment than the 500 µg/ml treatment again indicating acid stress.  
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Table 3.1. Metabolite profile for S. aureus grown with salicylate 
Metabolite 
Salicylate 
concentration 
Confidence 
Interval 
(µg/ml) (CI) 
Relative 
Abundance    
1,2-Benzenedicarboxylic acid 2500 500 2500 500 
1-Ethylglucopyranoside 2.3 2.6 1.11 0.39 
1-Methyl-beta-D-galactopyranoside NA 1.1 NA NA 
1-Monooctadecanoylglycerol 0.4 0.7 NA 0.16 
2(1H)-Pyrimidinone, 1-D-ribofuranosyl-4-
hydroxy-5'-p 1.4 1 0.38 0.38 
2,3-hydroxybutane 0.4 0.5 0.98 0.38 
2,3-hydroxysuccinic acid 1.2 1.3 0.15 0.1 
2,4,6-hydroxypyrimidine 1.3 1.1 0.33 0.33 
2,4,6-Tri-tert.-butylbenzenethiol 0.5 1.5 0.38 0.22 
2,4-hydroxybenzoic acid 1.7 1.7 0.21 0.69 
2,4-hydroxybutanoic acid 3.3 2.7 0.65 0.98 
2-Amino-4,6-dihydroxypyrimidine 1 0.9 0.65 0.65 
2-Aminobutyric acid 1.2 1.7 0.15 0.35 
2-aminoethylphosphoglycerate NA 0.5 0.37 0.68 
2-Furancarboxylic acid 0.5 NA NA 0.15 
2-hydroxybenzoic acid 0.7 0.9 0.34 NA 
2-hydroxybutanoic acid 528.2 166.6 0.16 0.16 
2-Hydroxyglutaric acid 0.9 1 306.07 176.77 
2-Ketogluconic acid 0.6 0.8 0.31 0.12 
2-methyl-2,3-hydroxypropanoic acid 6.7 8.8 0.12 0.29 
2-methyl-2-hydroxybutanoic acid 0.7 0.7 10.43 7.36 
2-methylbenzoic acid 1.3 1.7 0.03 0.24 
2-oxo-3-hydroxypropanoic acid 1.9 1.9 0.95 1.52 
2-oxophosphoglycerate 0.8 0.6 0.38 0.39 
2-phosphoglycerate 0.9 1.1 0.57 0.36 
3,4,5-Trihydroxypentanoic acid 0.1 0.3 0.32 0.12 
3,4-Dihydroxybutanoic acid 2.4 4.7 0.03 0.11 
3-methyl-3-hydroxybutanoic acid 1.2 2.1 0.2 2.72 
3-phosphoglycerate 1.3 1.4 0.14 1.32 
4,5-dimethyl-2,6-hydroxypyrimidine 1 1.1 0.2 0.21 
4-Hydroxybutanoic acid 0.4 0.2 0.3 0.46 
aconitic acid 0.9 1.3 0.29 0.15 
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Table 3.1 continued  
Metabolite 
Salicylate concentration Confidence Interval 
(µg/ml) (CI) 
Relative Abundance    
Adenosine NA 0.3 0.13 0.12 
Adenosine-5-monophosphate 0.2 0.6 NA 0.07 
a-Glycerophosphate 0.6 0.8 0.12 0.09 
Agmatine 0.4 1.1 0.14 0.16 
a-ketoglutaric acid 0.5 0.4 0.1 0.1 
Alanine 0.5 0.4 0.09 0.11 
Aminomalonic acid 0.8 0.5 0.15 0.11 
arabitol 0.1 0.4 0.19 0.07 
Asparagine 0.9 1.2 0.18 0.21 
Aspartic acid 0.3 0.3 0.04 0.28 
B-alanine 1.1 1.2 0.11 0.14 
Benzoic acid 1.3 1.2 0.2 0.21 
Butylamine 1.3 1.4 0.45 0.07 
citric acid 1.1 1 0.16 0.21 
Diethyleneglycol 0.4 0.4 0.33 0.15 
digalactosylglycerol 1.1 1.3 0.08 0.11 
Eicosanoic acid 0.6 1 NA NA 
erythronic acid 1.6 1.3 0.26 0.39 
ethanolamine 1 1.3 0.09 0.48 
Ethyl phosphoric acid 0.9 1 NA NA 
Ferulic acid 0.4 0.8 0.76 0.45 
fructose 1 0.7 0.14 0.44 
Fructose-6-phosphate 0.2 0.3 0.25 0.55 
Fumaric acid 1 2.3 0.09 0.51 
Galactaric acid 0.7 0.6 0.23 0.04 
galactose 0.3 0.2 0.13 0.21 
Glucaric acid 0.5 0.7 0.24 1.28 
Glucoheptulose 0.2 0.3 0.1 0.15 
Gluconic acid 0.5 0.9 0.13 0.09 
glucose 1.6 1.6 0.18 0.11 
glucose-6-phosphate 0.2 0.5 0.07 0.17 
Glutamic acid 0.4 0.3 0.25 0.65 
Glutaric acid 0.3 0.5 0.79 0.67 
galactose 0.3 0.2 0.13 0.21 
Glucaric acid 0.5 0.7 0.24 1.28 
Glucoheptulose 0.2 0.3 0.1 0.15 
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Table 3.1 continued 
Metabolite 
Salicylate concentration Confidence Interval 
(mg/ml) (CI) 
Relative Abundance    
Gluconic acid 0.5 0.9 0.13 0.09 
glucose 1.6 1.6 0.18 0.11 
glucose-6-phosphate 0.2 0.5 0.07 0.17 
Glutamic acid 0.4 0.3 0.25 0.65 
Glutaric acid 0.3 0.5 0.79 0.67 
Glyceric acid 0.8 1 0.11 0.34 
Glycerol 0.9 0.8 0.22 0.11 
Glycine 1 2.3 0.16 0.36 
glycolic acid 0.5 0.5 NA NA 
Glycopyranose 0.9 1.1 0.04 0.23 
Guanine 0 0.2 0.32 0.22 
Hexadecanoic acid 1.5 0.9 0.93 1.75 
Hexanoic acid 1.2 1 0.47 0.1 
Hydroxylamine 0.2 0.7 0.69 0.26 
Hydroxyphosphinyloxy-acetic acid 0.7 1.1 0.87 0.36 
Hydroxyproline 1.2 1.1 0.69 0.53 
Inositol, chiro- 0.8 1.4 0.29 0.33 
inositol, myo- 0.7 0.8 0.06 0.25 
Inositol, scyllo- 0.6 0.7 0.11 0.44 
isoleucine NA 1 NA NA 
Isoxanthopterin 0.7 0.7 0.3 1 
lactic acid 3.2 0.9 0.13 0.16 
lactose 1.7 1.1 0.31 0.18 
leucine 0.7 0.3 NA 0.68 
lysine 0.6 1.2 0.09 0.3 
Maleic acid 0.6 0.3 3.4 0.16 
Malic acid 1.1 1.2 0.7 0.05 
Malonic acid 0.4 0.6 0.25 0.14 
Mannitol 1 0.8 0.19 1.47 
mannose 1.7 1.8 0.29 0.2 
mannose-6-phosphate 2 1.1 0.33 0.37 
Melibiose 0.9 0.9 0.17 0.49 
methionine 1 1.2 0.15 0.23 
Methylmalonic acid 0.6 0.7 0.55 1.18 
Monomethylphosphate NA 1.1 1.34 0.05 
N-Acetyl aspartic acid 1.2 1 0.38 0.45 
N-Acetylglutamic acid 0.7 1.1 0.62 0.82 
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Table 3.1 continued 
Metabolite 
Salicylate concentration Confidence Interval 
(mg/ml) (CI) 
Relative Abundance    
N-Acetyl-Lysine 0.6 0.9 0.4 0.16 
N-Acetyl-serine 0.7 0.6 NA 0.54 
Nicotinic acid 1 1 0.3 0.54 
Nonanoic acid 0.9 0.8 0.5 0.13 
Octadecanoic acid 1.1 0.9 0.33 0.04 
Octadecanol 1.5 1.3 0.21 0.2 
ornitine 0.8 0.9 0.32 0.11 
Orotic acid 0.2 0.5 0.46 0.09 
oxalic acid 1 0.8 0.63 0.57 
Panthotenic acid 0.5 0.5 0.99 0.45 
phenylalanine 0.6 0.6 0.11 0.11 
phosphoric acid 0.6 0.7 0 0.54 
Pinitol 0.6 0.6 NA 0.22 
Pipecolic acid 0.8 1.2 0.56 0.37 
Pyroglutamic acid 1.2 1.9 0.24 0.09 
pyrophosphate 0.6 0.5 0.12 0.28 
Pyrrole-2-carboxylic acid 3 1.9 NA NA 
pyruvic acid 0.5 1.3 0.13 0.32 
ribitol 0.7 1.1 0.48 0.04 
ribose 0.8 1 0.28 0.39 
ribose-5-p 1.3 2.3 0.2 1.13 
Sedoheptulose 0.9 1 0.15 0.2 
serine 0.8 0.8 2.26 0.59 
Sorbitol 0.6 0.6 NA 0.33 
sorbose 0.5 0.8 0.15 0.21 
Succinic acid 0.6 1 0.6 0.52 
sucrose 1 1 0.51 1.7 
Threonic acid 0.3 0.2 0.17 0.41 
Threonine 4.4 5.2 0.1 0.06 
Thymine 0.9 1.1 0.35 0.25 
Trehalose 0.5 0.5 0.55 0.11 
Tryptophan 0.5 0.2 0.18 0.12 
tyrosine 0.5 0.3 0.32 0.43 
Uracil 0.7 0.5 0.09 0.16 
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Table 3.1 continued 
Metabolite 
Salicylate concentration Confidence Interval 
(mg/ml) (CI) 
Relative Abundance    
Uridine 1.2 0.7 NA NA 
valine 0.4 0.8 NA NA 
vanillic acid 0.7 0.8 6.49 3.17 
xylitol 1 1 0.14 0.7 
 
All values mean fold change and are relative to the control, non-salicylate treated 
treatment. 
Not recorded (NA). 
  
The effects of salicylate on the TCA cycle  
Metabolite profiling revealed down regulation of glycolysis as well as the TCA 
cycle. We therefore wanted to determine the effect of salicylate on the TCA cycle. These 
findings correlated to a significant increase in levels of NAD+ in cells treated with 2500 
µg/ml salicylate for 3 hours with a p=0.036 (Fig. 3.2). Ciprofloxacin, a positive control, 
has been shown to result in an increase in NAD+ levels [89]. No increase in NAD+ levels 
was detected at the 500 µg/ml treatment of salicylate. Oxygen dependence has been 
linked to downregulation of the electron transport chain and the TCA genes and can be 
seen through a decrease in NADH levels (Fig. 3.3) as well as the buildup of lactic acid 
and butanediol as we have seen through the metabolite profile (Table 3.1) [145]. 
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Figure 3.2. Effect of salicylate on cellular NAD+ levels. Mean (n≥3) percent 
nicotinomide adeninine dinucleotide (NAD+) plotted for ciprofloxacin and different 
salicylate concentrations, at time 0 (filled) and 3 h after treatment (stippled). Asterisks 
denotes statistical significance p<0.05 when compared to identical treatment at time 0. 
 
 
Oxygen dependence on the SAGAR phenotype 
 
Oxygen has been shown to play an important role in the persistence and overall 
growth of S. aureus in different conditions [145]. We were interested in determining the 
oxygen dependence on the genotypic heritable phenotype. As shown in Fig. 3.3, in the 
presence of oxygen there were 6.5-fold more cells recovered on 1 µg cipro plus 500 
µg/ml salicylate plates when compared to the number of cells recovered in the absence of 
oxygen, 2.6 x 10-6 to 3.9 x 10-7. This shows an inverted phenotype in the absence of 
oxygen, which implies a dependence on oxygen or aerobic growth for this phenotype to 
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be expressed. On the other hand, at 2500 µg/ml of salicylate and 1 ug ciprofloxacin, there 
was no difference observed between treatments. This indicates that the effect observed at 
2500 µg/ml of salicylate is linked to toxicity rather than oxygen availability (Fig 3.3). 
Also, the SAGAR phenotype was recapitulated in that the addition of 500 µg/ml 
salicylate increased frequency of ciprofloxacin resistant isolates by 10.3-fold when 
compared to without salicylate aerobically. 
 
Figure 3.3. Expression of SAGAR during anaerobic growth. Mean (n=3) fold change in the 
frequency of mutation to CipR for anaerobic cultures relative to aerobic cultures plotted for 
growth on ciprofloxacin (control), and ciprofloxacin with 500 µg/ml or 2500 µg/ml salicylate.  
 
Role for reactive oxygen in the SAGAR phenotype  
Salicylate has been shown to result in reactive oxygen species (ROS) 
accumulation in mitochondria [82, 147]. ROS damages DNA resulting in oxidation of 
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guanine to 8-oxo-7, 8-dihydro-guanine, which can result in mutations [148]. To gain 
further insight into the role for ROS in the SAGAR phenotype, ROS levels were recorded 
using either DCFH-DA (Fig. 3.4 A) or luminol (Fig. 3.4 B). ROS levels from salicylate 
stressed cells were compared to levels recorded from 100 µM CCCP, a positive control, 
and the control treatment, which were SH1000 cells grown in the absence of any stressor. 
A statistical significance with a p<0.05 was only observed with the positive controls (Fig. 
3.4 AB). Specifically, a 2.7-fold and 6-fold increase in ROS was observed for CCCP 
when compared to the control for DCFH-DA and luminol, respectively. However, no 
increase in ROS was observed for both DCFH-DA and luminol for 500 and 2500 µg/ml 
salicylate or the negative control, 04 % glycerol. 
Fluoroquinolones are known to result in ROS accumulation [89]. We 
hypothesized that since the genotypic heritable phenotype is only observed in the 
presence of salicylate and an antibiotic such as ciprofloxacin, that we would detect ROS 
in the presence of both drugs. Therefore, combinational effects of salicylate with 
ciprofloxacin were tested for ROS levels (Fig. 3.4 C). ROS accumulation was observed at 
1 µg/ml ciprofloxacin and also when combined with salicylate. However, ROS levels 
were lower in the presence of salicylate when combined with ciprofloxacin than with 
ciprofloxacin alone.  
Recently, in a study by Paez et al. 2010 [92], the addition of glutathione to 
ciprofloxacin treated cells was able to significantly reduce the MIC to ciprofloxacin 
resistant S. aureus cells. The ability of salicylate to induce ROS was addressed with the 
addition of glutathione, an antioxidant. The addition of glutathione to ciprofloxacin and 
salicylate stressed cells, as expected, mitigated the number of CFUs/ml recovered (Fig. 
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3.5) indicating antioxidant properties for glutathione. However, the addition of 
glutathione to ciprofloxacin alone or ciprofloxacin and salicylate treatments did not 
decrease ROS levels (Fig. 3.4 C) indicating that glutathione was mitigating the SAGAR 
phenotype in a different manner. Therefore, we believe that glutathione is not reducing 
ROS, but rather altering the structure of salicylate, which impairs the ability of salicylate 
to induce its genotypic effects. 
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Figure 3.4. Salicylate associated ROS accumulation. ROS accumulation using: (A) 
DCFH-DA (B) luminol. (C) Combinational effects of ciprofloxacin and salicylate on 
accumulation of ROS using luminol. Asterisks denote statistical significance compared to 
control with a p<0.05, n=3. All values were recorded after 3 hours of stress under each 
treatment. GSH indicates 10 mM glutathione. Cipro indicates 1 µg/ml ciprofloxacin. 
Salicylate indicates 500 µg/ml salicylate. CCCP indicates carbonyl cyanide m-
chlorophenylhydrazone. 
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Figure 3.5. The effects of glutathione on the SAGAR phenotype. Control treatment was 
strain SH1000 grown strictly in TSB. SH1000 cells were plated on TSA plates containing the 
above treatments. CFUs recovered were recorded. Asterisks denotes statistical significance with 
P<0.05 between cipro and salicylate treatment compared to cipro, salicylate and glutathione. 
GSH indicates 10 mM glutathione. Cipro indicates 1 µg/ml ciprofloxacin. Salicylate indicates 
500 µg/ml salicylate.  
 
 
3.4 Discussion 
The results of this study revealed that the SAGAR phenotype is sensitive to 
salicylate concentration; the phenotype is expressed at non-toxic concentrations, but is 
suppressed at growth-toxic concentrations. Growth toxic concentrations were associated 
with a metabolic switch to anaerobiosis, supported by the accumulation of lactic acid and 
butanediol in our metabolite profile. Accumulation of such metabolites implies that this 
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concentration of salicylate induced weak acid stress [138]. Mixed acid (lactate, formate, 
and acetate) and butanediol fermentation in S. aureus occur under anaerobic 
conditions[138]. Pyruvate from glycolysis can be reduced to either lactate by activity of 
lactate dehydrogenase or metabolized to acetoin and 2,3-butanediol by the activity of 
acetolactate synthase (BudB), α-acetolactate decarboxylase (BudA1), and acetoin 
reductase (SACOL0111) [138]. This process requires the oxidation NADH, which is a 
requisite under fermentation conditions [138]. 2,3-butanediol is involved in a variety of 
physiological activities such as homeostasis of pH and regulation of cellular 
NAD/NADH ratio in bacteria [145].  
 The anaerobic effect induced by growth toxic concentrations of salicylate led to 
question if the impairment in generation time was a causative or correlative effect. Under 
anaerobic conditions SAGAR for ciprofloxacin was substantially reduced suggesting a 
requirement of oxygen for the phenotype. Oxygen is necessary for the formation of a 
functional electron transport system [150]. It is possible that the lack of oxygen prevents 
ROS as well as DNA damage from occurring, i.e. an elevated mutation frequency, since 
regulation of the electron transport chain is vital to the homeostasis of S. aureus. This 
reveals that SAGAR requires an oxidative environment. 
ROS damages iron-sulfur clusters making ferrous iron available for oxidation by 
the Fenton reaction [84, 85]. The Fenton reaction leads to hydroxyl radical formation. 
The hydroxyl radicals damage DNA, proteins, and lipids, which results in cell death [84, 
85]. In a study by Chatterjee et al. inactivation of fur, a ferric uptake regulator homolog, 
decreased butA, which decreased 2,3-butanediol productions, as well as the TCA cycle 
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genes citC, isocitrase [147]. These findings support the idea that toxic concentrations of 
salicylate inhibit the TCA cycle, therefore, impairing the reduction of NAD+.  
 Salicylate in mitochondria has been shown to interact with the respiratory chain 
resulting in hydrogen peroxide and other ROS which in turn oxidize thiol groups and 
glutathione [131]. This oxidative stress leads to the induction of the mitochondrial 
permeability transition in the presence of Ca2+. This leads to further increase of oxidative 
damage, resulting in impairment of oxidative phosphorylation [131]. Based on these 
findings we hypothesized that salicylate would result in ROS accumulation in S. aureus 
cells. However, contrary to our hypothesis, induction of growth toxic and non-growth 
toxic concentrations of salicylate did not result in detection of ROS using either 
chemiluminescent DCFH-DA or luminol. Fluoroquinolones, specifically ciprofloxacin, 
have been shown to result in ROS production, which is one of their main bactericidal 
characteristics [85, 105, 106, 108, 146, 148, 149]. Considering that the mutation 
frequency observed is always in the presence of an antibiotic, such as ciprofloxacin, we 
hypothesized that the combination of salicylate and ciprofloxacin would result in a 
significant increase in ROS. We however, did not observe ROS accumulation upon the 
combination of both drugs. Also, the addition of glutathione, an antioxidant, did not alter 
the levels of ROS produced for both ciprofloxacin and salicylate, which leads to conclude 
that salicylate does not result in detectable ROS accumulation in S. aureus. However, the 
addition of glutathione to ciprofloxacin and salicylate treatments did substantially 
mitigate the SAGAR phenotype. This suggests that glutathione may not be acting like an 
antioxidant, but rather could be altering the structure of salicylate. Alteration in the 
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structure of salicylate, as seen in Chapter 2 results section 2.3, also mitigates the SAGAR 
phenotype.  
A significant increase in mutation frequency is observed at non-growth toxic 
concentrations of salicylate (500 µg). Despite the lack of ROS accumulation, metabolite 
profiling revealed a decrease in glycolysis and TCA cycle as seen in decreased levels of 
citric acid, acontic acid, α-ketoglutaric acid, and fumaric acid, which was not mirrored in 
the increase in NAD+ levels at 500 µg/ml of salicylate. However, at growth toxic 
concentrations of salicylate (2500 µg/ml), a significant increase in NAD+ levels was 
observed, indicating either an increase in the oxidation of NADH or rather impairment in 
TCA cycle, which is responsible for reducing NAD+. It is possible that the disruption of 
the TCA cycle in addition to the growth impairment effects of salicylate at 2500 µg/ml in 
combination are responsible for the toxicity and in result are responsible for mitigation of 
the SAGAR phenotype. 
 Another effect observed with toxic concentrations of salicylate by Riordan et al. 
[42] is a significant decrease in transcription of glycolytic genes gapA2 and pgi, which 
are important genes in this process. Also, a significant increase in the gluconate operon 
(gntkPR) was observed upon salicylate stress [42]. Interestingly, Riordan et al. [42] 
observed exacerbation and reduction in growth inhibitory effects of salicylate upon 
glucose and gluconate addition, respectively. We cared to further explore this observation 
with a wide range of fermentable and non-fermentable sugar sources in a sugar free 
media, CASY (data not shown). We did not see any sugar that significantly impaired  
growth toxic effects of salicylate when compared to treatments of salicylate in the 
absence of a sugar source. We did however; observe that glucose exacerbated the 
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inhibitory effects of growth toxic concentrations of salicylate (data not shown). We 
hypothesized that this effect was due to a decrease in pH, which altered membrane 
permeability and in result enhancing the toxicity of salicylate. To test this hypothesis we 
used a buffer, MOPS to determine if it was in fact an acid effect (data not shown). As 
hypothesized, lowering the pH decreased the concentration of salicylate needed to inhibit 
growth. This finding leads us to believe that it is in fact the acidification of media that 
results in alteration of membrane permeability. This finding was observed in Serratia 
marcescens [89]. The effect of salicylate has been attributed to a weak acid effect that 
possibly leads to an increase in the membrane potential [89]. 
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